Annie’s Recommended a Buy on Weakness and Stock Analyses to Track

SodaStream International Ltd. (NASDAQ:SODA):  Current price $50.3899

After meeting with SodaStream International Ltd.’s management, Oppenheimer thinks that the company’s strong operating momentum should continue into 2013. Oppenheimer reported that the company said they had a strong fourth quarter, and they believe that the company’s United States sales and profitability will be set to increase significantly. The firm reiterates an Outperform rating on the stock.

soda

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Annie’s, Inc. (NYSE:BNNY): Current price $36.30

Following last night’s product recall announcement, J.PMorgan recommends buying shares of Annie’s, Inc. on any significant weakness. After speaking with management, JPMorgan said that they are confident the company’s sales trends ex-pizza are very strong. The firm lowered their price target for shares from $50 to $45, but keeps an Overweight rating on the stock.

bnny

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

W.R. Grace & Co. (NYSE:GRA): Current price $71.43

Ahead of the company’s fourth quarter results, Piper Jaffray raised their price target for W.R. Grace & Co. and keeps an Overweight rating on the stock. Piper sees Albemarle’s (NYSE:ALB) results as a positive for W.R. Grace.

grs

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Verizon Communications Inc. (NYSE:VZ): Current price $42.60

After Verizon Communications Inc. reported lower than expected fourth quarter earnings per share, Oppenheimer believes the results were solid and expects the company’s profits to jump significantly over the next several quarters. The firm expects the company’s 2013 EPS to reach record levels and they maintain an Outperform rating on the stock.

vz

 

Celgene Corporation (NASDAQ:CELG): Current price $98.33

After the company reported survival data for their Abraxane treatment for pancreatic cancer, Stifel Nicolaus increased their target on Celgene Corporation. The firm thinks the 1.8 month overall survival benefit just meets the bar for clinical meaningfulness, and they raised their sales estimate for the treatment significantly. The firm maintains a Buy rating on the stock.

celg

Don’t Miss: Is This Apple’s New Samsung Repellant?